# US 2024/0002850 A1 · SIRT1-saRNA Compositions and Methods of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002850 A1
- Document ID: US20240002850A1
- Status: Published application
- Kind: A1
- Application number: 18/086,209
- Filed: 2022-12-21
- Published: 2024-01-04
- Earliest claimed: 2018-04-12
- Assignees: Mina Therapeutics Limited
- Applicants: MiNA Therapeutics Limited
- Inventors: Siv Anita Hegre; Pinelopi Andrikakou; Vikash Reebye
- Web page: https://patentgrep.com/patent/US20240002850A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/30: Chemical structure
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a saRNAs useful in upregulating the expression of the SIRT1 gene and therapeutic compositions comprising the saRNA. Methods of using the saRNA and the therapeutic compositions are also provided.

## Claims

### Claim 1

A synthetic isolated saRNA which up-regulates the expression of the SIRT1 gene, wherein the saRNA comprises a strand that is at least 80% complementary to a targeted sequence on the template strand of the SIRT1 gene, wherein the targeted sequence comprises the sequence of any one of SEQ ID No. 3-24.

### Claim 2 (depends on 1)

The saRNA of claim 1, wherein the saRNA is single-stranded and comprises 14-30 nucleotides in length.

### Claim 3 (depends on 2)

The saRNA of claim 2, wherein the saRNA comprises the sequence of any one of SEQ ID NO: 47-51 or 53-68.

### Claim 4 (depends on 2)

The saRNA of claim 2, wherein the saRNA comprises a 3′ overhang.

### Claim 5 (depends on 4)

The saRNA of claim 4, wherein the saRNA comprises the sequence of any one of SEQ ID NO: 91-95 or 97-112.

### Claim 6 (depends on 1)

The saRNA of claim 1, wherein the saRNA is a saRNA duplex comprising an antisense strand and a sense strand, wherein each strand is independently 14-30 nucleotides in length.

### Claim 7 (depends on 6)

The saRNA of claim 6, wherein the antisense strand of the saRNA comprises the sequence of any one of SEQ ID NO: 47-51 or 53-68.

### Claim 8 (depends on 7)

The saRNA of claim 7, wherein the sense strand of the saRNA comprises the sequence of any one of SEQ ID NO: 25-29 or 31-46.

### Claim 9 (depends on 6)

The saRNA of claim 6, wherein the antisense strand of the saRNA comprises a 3′ overhang.

### Claim 10 (depends on 9)

The saRNA of claim 9, wherein the antisense strand of the saRNA comprises the sequence of any one of SEQ ID NO: 91-95 or 97-112.

### Claim 11 (depends on 10)

The saRNA of claim 10, wherein the sense strand of the saRNA comprises the sequence of any one of SEQ ID NO: 69-73 or 75-90.

### Claim 12 (depends on 1)

The saRNA of claim 1, wherein the saRNA comprises at least one chemical modification.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising the saRNA of claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 14 (depends on 1)

A method of up-regulating the expression of the SIRT1 gene, comprising administering the saRNA of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the expression of the SIRT1 gene is increased by at least 30%.

### Claim 16 (depends on 14)

The method of claim 14, wherein the expression of the SIRT1 gene is increased by at least 40%.

### Claim 17 (depends on 14)

The method of claim 14, wherein the expression of the SIRT1 gene is increased by at least 50%.
